Expression of PTPRZ1 in oral squamous cell carcinoma originated from oral submucous fibrosis and its clinical significance

doi:10.19439/j.sjos.2017.02.015

Abstract

Abstract: PURPOSES: This study was aimed to detect the expression of PTPRZ1 in oral squamous cell carcinoma (OSCC) originated from oral submucous fibrosis (OSF), and discuss its role in the development and progression of OSCC originating from OSF as well as its clinical significance. METHODS: Immunohistochemisty (IHC) and Western blot (WB) for the expression and distribution of PTPRZ1 were carried out in 36 cases of OSF transforming into OSCC, 23 cases of OSCC and 21 cases of healthy controls. The data were analyzed by Chi-square test using SPSS 21.0 software package. RESULTS: IHC results demonstrated that the expression of PTPRZ1 in OSCC originated from the OSF was strongly positive and the rate of positive expression was 72.22%; expression of PTPRZ1 in OSCC was weakly positive, the positive rate was 43.47%; and the expression of PTPRZ1 in healthy controls was negative. The rate of PTPRZ1 positive expression was significantly higher in OSCC originated from OSF and OSCC with non-OSF than that of the healthy controls (P<0.01). The positive expression rate of OSCC originated from OSF was significantly higher than that of OSCC with non-OSF (P<0.05).WB results showed the expression of PTPRZ1 was weak in the healthy controls and in OSCC with non-OSF, but strong in OSCC originated from OSF. Correlation analysis between PTPRZ1 and clinical data showed PTPRZ1 was correlated with recurrence and metastasis positively (r_k=0.642, P<0.05; r_k =0.656, P<0.05). CONCLUSIONS: Differential expression of PTPRZ1 in OSCC originating from OSF and OSCC with non-OSF was significant. PTPRZ1, which plays an important role in the processes of development, invasion and metastasis of OSCC originated from OSF, can be used as a molecular marker for early diagnosis and targeted gene for treatment of OSCC originating from OSF.

Key words: Protein tyrosine phosphatase receptor type Z1, Oral submucous fibrosis, Oral squamous cell carcinoma

CLC Number:

R739.8

ZHU Rong, JIAN Xin-chun, LIU De-yu, ZHOU Chao, WANG Yuan. Expression of PTPRZ1 in oral squamous cell carcinoma originated from oral submucous fibrosis and its clinical significance[J]. Shanghai Journal of Stomatology, 2017, 26(2): 198-203.

References

[1] 吴狄, 邓祥, 王坤, 等. 蛋白酪氨酸磷酸酶(PTPs)及其抑制剂的研究进展 [J]. 广州化工, 2012,40(9): 11-12.
[2] Labbé DP, Hardy S, Tremblay ML. Protein tyrosine phosphatases in cancer: friends and foes! [J]. Prog Mol Biol Transl Sci, 2012, 106: 253-306.
[3] Nikolaienko RM, Agyekum B, Bouyain S. Receptor protein tyrosine phosphatases and cancer: new insights from structural biology [J]. Cell Adh Migr, 2012, 6(4): 356-364.
[4] Ostman A, Hellberg C, Böhmer FD. Protein-tyrosine phosphatases and cancer[J]. Nat Rev Cancer, 2006, 6(4): 307-320.
[5] Hunter T. Signaling-2000 and beyond[J]. Cell, 2000, 100(1): 113-127.
[6] Makinoshima H, Ishii G, Kojima M, et al. PTPRZ1 regulates calmodulin phosphorylation and tumor progression in small-cell lung carcinoma [J]. BMC Cancer, 2012, 12: 537.
[7] Yi T, Lindner D. The role and target potential of protein tyrosine phosphatases in cancer[J]. Curr Oncol Rep, 2008, 10(2):114-121.
[8] Perez-Pinera P, Zhang W, Chang Y, et al. Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation [J]. J Biol Chem, 2007, 282(39): 28683-28690.
[9] Wu CW, Kao HL, Li AF, et al. Protein tyrosine-phosphatase expression profiling in gastric cancer tissues[J]. Cancer Lett, 2006, 242(1): 95-103.
[10] 翦新春, 沈子华, 刘蜀凡. 口腔黏膜下纤维性变(附2例报告) [J]. 临床口腔医学杂志, 1985, 1(1): 12-13.
[11] Paymaster JC. Cancer of the buccal mucosa. A clinical study of 650 cases in Indian patients [J]. Cancer, 1956, 9(3): 431-435.
[12] Murti PR, Bhonsle RB, Pindborg JJ, et al. Malignant transformation rate in oral submucous fibrosis over a 17-year period[J]. Community Dent Oral Epidemiol, 1985, 13(6): 340-341.
[13] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Betel-quid and areca-nut chewing and some areca-nut derived nitrosamines [J]. IARC Monogr Eval Carcinog Risks Hum, 2004, 85: 1-334.
[14] Garzino-Demo P, Dell'Acqua A, Dalmasso P, et al. Clinicopathological parameters and outcome of 245 patients operated for oral squamous cell carcinoma [J]. J Craniomaxillofac Surg, 2006, 34(6): 344-350.
[15] 郭峰. OSF癌变侵袭转移的临床研究及其与Wnt途径异常激活关系的初步研究[D]. 长沙: 中南大学, 2009.
[16] Song JJ, Liu J, Tolia NH, et al. The crystal structure of the Argonaute2 PAZ domain reveals an RNA binding motif in RNAi effector complexes [J]. Nat Struct Biol, 2003, 10(12): 1026-1032.
[17] 史一搏, 赵涵芳. 蛋白酪氨酸磷酸酶家族及其生理作用 [J]. 生命的化学, 2007, 27(4): 312-314.
[18] Shitara K, Yamada H, Watanabe K, et al. Brain-specific receptor-type protein-tyrosine phosphatase RPTP beta is a chondroitin sulfate proteoglycan in vivo [J]. J Biol Chem, 1994, 269(31): 20189-20193.
[19] Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer [J]. Cancer Lett, 2004, 204(2): 127-143.
[20] Liu YT, Shang D, Akatsuka S, et al. Chronic oxidative stress causes amplification and overexpression of ptprz1 protein tyrosine phosphatase to activate beta-catenin pathway[J]. Am J Pathol, 2007, 171(6): 1978-1988.
[21] Tamura H, Fukada M, Fujikawa A, et al. Protein tyrosine phosphatase receptor type Z is involved in hippocampus-dependent memory formation through dephosphorylation at Y1105 on p190 RhoGAP [J]. Neurosci Lett, 2006, 399(1-2): 33-38.
[22] Pariser H, Perez-Pinera P, Ezquerra L, et al. Pleiotrophin stimulates tyrosine phosphorylation of beta-adducin through inactivation of the transmembrane receptor protein tyrosine phosphatase beta/zeta [J]. Biochem Biophys Res Commun, 2005, 335(1): 232-239.
[23] Pariser H, Ezquerra L, Herradon G, et al. Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta-signaling pathway: regulation of tyrosine phosphorylation of Fyn by pleiotrophin [J]. Biochem Biophys Res Commun, 2005, 332(3): 664-669.
[24] Meng K, Rodriguez-Pena A, Dimitrov T, et al. Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta [J]. Proc Natl Acad Sci USA, 2000, 97(6): 2603-2608.
[25] Benaim G, Villalobo A. Phosphorylation of calmodulin. Functional implications[J]. Eur J Biochem, 2002, 269(15): 3619-3631.
[26] Corti C, Leclerc LE, Quadroni M, et al. Tyrosine phosphorylation modulates the interaction of calmodulin with its target proteins [J]. Eur J Biochem, 1999, 262(3): 790-802.
[27] Williams EL, Djamgoz MB. Nitric oxide and metastatic cell behaviour [J]. Bioessays, 2005, 27(12): 1228-1238.
[28] Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression [J]. Nat Rev Cancer, 2006, 6(7): 521-534.
[29] Eyler CE, Wu Q, Yan K, et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2 [J]. Cell, 2011, 146(1): 53-66.
[30] Wang V, Davis DA, Veeranna RP, et al. Characterization of the activation of protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1) by hypoxia inducible factor-2 alpha [J]. PLoS One, 2010, 5(3): e9641.
[31] Jeong HC, Kim GI, Cho SH, et al. Proteomic analysis of human small cell lung cancer tissues: up-regulation of coactosin-like protein-1 [J]. J Proteome Res, 2011, 10(1): 269-276.